AA
ZNTL icon

AlphaCentric Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

AlphaCentric Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,000
Closed -$217K – 243
2021
Q1 		$217K Buy
+5,000
New +$215K 0.07% 90

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlphaCentric Advisors's ZNTL Position: Q2 2021 in Review

AlphaCentric Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2021, closing a stake of 5,000 shares — an estimated $217K sold.

AlphaCentric Advisors first reported a position in ZNTL in Q1 2021 and held it in 1 quarter. The position peaked at $217K in Q1 2021. 120 funds tracked by Wall St. Rank hold ZNTL as of Q2 2021.

  • AlphaCentric Advisors reported no remaining Zentalis Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 5,000 Zentalis Pharmaceuticals shares in Q2 2021, an estimated $217K.
  • AlphaCentric Advisors first reported a position in Zentalis Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • AlphaCentric Advisors's Zentalis Pharmaceuticals position peaked at $217K in Q1 2021.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2021.

Based on AlphaCentric Advisors's 13F filing for Q2 2021, filed 9 Mar 2022.